Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey everyone,
I just want to put things into persective a bit... think about how long some of us have been here. I've been a shareholder well before I knew Ihub even existed. Now, think about how quickly two months go by.
How excited would you have been to hear last year at this time that we'd be going commercial in TWO MONTHS!?
This would be a major milestone in any company's lifespan, and I think all the longs here can agree that AEMD is especially poised for growth after we get market acceptance!
What stock don't they manipulate?
Here's to hoping for a shareholder letter that coincides with the conference..
So, we get a commercialization update in two days... I'll take it.
Hah, yea, I was just being sarcastic.. just want something soon.
I want to see a shareholder letter that includes a line that says they were offered to be bought for $15 a share.
Is that too much to ask for?
Nice close, two green days in a row. I thought for sure we'd be red after yesterday, maybe we're starting back up?
This stock has always moved fast in both directions. I'm afraid it got a lot of attention from WU and Sheff.. lots of people bought at the same time, and lots sold at the same time without doing any real DD.
I am skeptical myself that the Ihub community has that much power, but given the lack of volume before the last run, it wouldn't take many people jumping in at once to make it move.
I just read that... this could bring some publicity to AEMD.
Beyond that, according to the NY Times article:
"Using techniques that can be administered only after a patient has died, doctors have identified C.T.E. in all six N.F.L. veterans between ages 36 and 50 who have been tested for the condition, further evidence of the dangers of improperly treated brain trauma in football."
There seems to be some market potential here if they can identify the biomarkers in the blood of current, living NFL players and even children just starting to get into the sport. What better way to look for them than with the correct affinity agents within the hemopurifier?
Is it a presentation or jsut a poster session?
I generally like his stuff... but one wonders where he'd be without capitalism (or is it greed?)? How much did he make from that movie?
I suspect we'll get news or a shareholder letter this afternoon or Monday regarding how the presentation went with info such as total attendence, etc, along with the results in lay terms.
89 boardmarks.. practially quadrupled in less than three weeks.
For all the new investors, consider listening to the AEMD CEO on redchip radio:
http://www.redchip.com/visibility/Radio/radioMain.asp
Bottom left of that page... enjoy
Maybe there's a redchip representative at the conference? Surely they want as much exposureas possible, too.
Remember, tomorrow is the nephrology conference where AEMD CEO will present data regarding treatment of HCV (the company's primary focus to begin commercialization) with their Hemopurifier:
Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
Thursday 10/15/2009 8:00 AM ET - Pr Newswire
As of 2:44 PM ET 10/29/09
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier(R) will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier(R) studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier(R) treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.
http://www.hcvadvocate.org/hcsp/articles/current_standards_2006.html
AEMD is about to throw a curveball at whoever wrote this article :)
"Tomorrow’s Standard of Care?
Currently, there are new therapeutic approaches being investigated in an effort to augment SVR rates in all patient groups, especially those who currently have a poor response to therapy. Several novel IFNs, interferon delivery systems, IRES inhibitors, ribavirin-like molecules, protease and polymerase inhibitors, newer immunomodulators, and other hepatitis C replication enzyme inhibitors are currently being studied in clinical trials. In addition, antifibrotic agents, caspase inhibitors and antibody therapies and vaccines are also under development."
With all these pharmas competing for their drug to get the SOC stamp.. do you think it's plausible that JJ is waiting to choose a strategic partner until after one of the companies emerges as the winner?
That way, he can go to them specifically with scientifically proven, empirical evidence that he has a product that will help them. If they choose not to partner under JJ's terms, he goes to the second leading SOC drug candidate company and that company now has the means to out perform whichever one orignally wins (if they make the mistake of not partnering with AEMD)
Beautiful day of trading after a few days of cooling off/consolidation.. it wants to close HOD so soo badly heading into tomorrow:
Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
Thursday 10/15/2009 8:00 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
AEMD 0.488 13.49%
As of 2:44 PM ET 10/29/09
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier(R) will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier(R) studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier(R) treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.
That's 1-3 PM eastern, I'm guessing it'll be perfect for tomorrow's trading as well.
Also, want to reiterate my excitement for Exosome Sciences... this could be it's own multimillion dollar beast someday wholly, owned by us shareholders, of course ;)..
Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
Thursday 10/15/2009 8:00 AM ET - Pr Newswire
As of 2:44 PM ET 10/29/09
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier(R) will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier(R) studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier(R) treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.
Where did he move to?
Back to HOD at .5, +16%
This is from the article that was published about exosomes in The Journal of Translational Medicine:
"Conclusion
The Hemopurifier™ cartridge can enter the cancer therapeutics
arena with relative ease due to several factors.
Firstly, the cartridge is already produced under Good
Manufacturing Practices with clinical safety data available,
albeit for different indications. Secondly, the cartridge is
compatible with standard dialysis systems which are
present at every major medical institution. Thirdly, the
patient population whose treatment is proposed with this
novel approach has few or no treatment alternatives.
Fourthly, the Hemopurifier™ cartridge can be used not
only as a monotherapy, but also as an adjuvant to currently
used immunotherapeutic approaches. The commercialization
of therapies as adjuvants to existing
therapies is well-accepted in the industry, as seen in the
approval of Herceptin and Avastin for use with specific
chemotherapeutic agents.
In conclusion, the use of the Hemopurifier™ as a means of
de-repressing immune functions in cancer patients is a
novel, easily implemented approach to cancer therapeutics
that will not only provide an alternative to the currently
ineffective approaches, but also provide a
framework for development of strategies that may benefit
cancer patients in a multidimensional manner."
If anyone would like the full article, PM me your e-mail and I will send it right away.
Exosomes as a tumor immune escape mechanism: possible
therapeutic implications
Thomas E Ichim*1,2,9, Zhaohui Zhong†3, Shalesh Kaushal†4, Xiufen Zheng2,
Xiubao Ren5, Xishan Hao5, James A Joyce6, Harold H Hanley6,
Neil H Riordan1, James Koropatnick2, Vladimir Bogin1, Boris R Minev7,8,
Wei-Ping Min2 and Richard H Tullis6
We might get an alert from Redchip about the conference being webcast like monday's was.. I'd love te hear those results as they're released.
I also am expecting very positive data. Why else would they save it for the biggest nephrology conference in the country (world?)?
Is 'blackout' your own term for it or something JJ has referred to? I hope JJ doesn't take his foot off the gas now. Unlikely, IMO, with all the developments he referred to in during the investor conference on Monday.
However, I do think many Ihubbers are used to MOMO plays and pinksheet stocks that put out PR's every day. It's just silly, really.
JJ knows that his company is undervalued, that's all I care about for now. The news will come :)
Haha, that is actually a little funny. A little. You're entitled to your opinion but please back it up as much info as possible. Your initial claim was ridiculous.
No one cares and you're officially the first person ever on my ignore list, congrats.
This isn't a pinksheet stock and it's not a pinksheet message board.
Please put that crap somewhere else (maybe somewhere with a 'low OS'?) and do some real dd (or at least write honestly as if you've done ANY..)
your investment philosphy is buy low OS with future event, huh? You mean like presenting HCV data at Friday's conference? Interesting.
Thanks GWMAN..
I'm a little confused about the telepavir comparison, but only because I don't recall anything about the deal he referred to. Can you elaborate a bit? I no longer have access to the presentation and missed the background to those comments.
JJ is hitting this one out of the park, IMO.. awesome presentation so far.
How much bid support do we have?
I will be, but it doesn't start until 5:00 ET
AEMD should have a strong close with this lined up for AH:
Aethlon Medical Discloses Live Webcast of Today's BIOCOM Presentation
Monday 10/26/2009 5:00 AM ET - Pr Newswire
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed that today's presentation at the 4th Annual BIOCOM Investor Conference will be webcast live today. The presentation by Aethlon Chairman and CEO, James A. Joyce will begin at 2 p.m. pacific time and can be accessed on an audio-only basis at:
http://www.biocom.org/event/2009_Investor_Conference
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-
Aethlon at Forefront of Broad-Spectrum Virus Treatment With Hemopurifier (From June... RedChip Article)
As the world population continues to grow and distances between people dwindle, a different kind of threat to personal safety, other than bullets, bombs, natural disasters or accidents, is much on the minds of our globally connected population: germs. More specifically, global pandemics of deadly germs.
According to the World Health Organization, nearly 36 thousand people in 76 countries have been infected with the H1N1 virus (Swine flu), causing 163 deaths. As fears that the virus may mutate to a more potent strain mount, the lesson is clear: more people plus more travel equals more germ transmission. While outbreaks of deadly diseases in the past (and present) such as Typhoid fever and influenza are horrific, humankind’s effort and scientific achievements in the name of combating such diseases are truly awe-inspiring.
One such innovator is Aethlon Medical, Inc. (OTC BB: AEMD), developer of the Hemopurifier®. The Hemopurifier is a patented extracorporeal device that captures circulating viruses and viral proteins and toxins before the occurrence of cell and organ infection. The filtration device has already seen significant results in the treatment of HIV, Hepatitus C, Marburg, Ebola, Measles, Mumps, influenza (including the strain of H1N1 that left 57 people dead in the U.S. earlier this year), and Orthopox virus. The Hemopurifier is classified as a broad-spectrum antiretroviral — broad-spectrum inhibitors are naturally occurring antiviral compounds occurring in certain kinds of mushrooms and fungi.
On May 5, 2009, Aethlon reported the following:
“[A]n HIV-infected individual, who received 12 Hemopurifier® treatments during the span of one month, had an average viral load reduction of 55% during each four-hour Hemopurifier® treatment. The study was conducted in the absence of any antiviral drug therapy. Based on this data, mathematical treatment models of approximately 1.5 days of continuous Hemopurifier® treatment would reduce patient viral load to undetectable levels.”
The problem with viral diseases, as anyone who has received a flu shot in the spring knows, is that they are continually evolving. The AIDS and HIV viruses are the most notorious cases of this, and their continually evolving resistance to treatment methods makes them among some of the deadliest in the world. Treatments for such viruses involve multiple-medication “cocktails” taken several times a day, and side effects can include nausea, diarrhea, malaise, and fatigue. Tantamount to finding effective treatments is the goal of finding treatments that improve the patient’s quality of life overall as well as reduce viral load in the bloodstream, as months of treatment can be physically, mentally and emotionally debilitating.
Aethlon’s Hemopurifier is remarkable not only because initial observations from the HIV study indicate the device could inhibit and reverse HIV disease progression in the absence of antiviral drugs but also because the same device may be usable for treating different viral diseases. Since the beginning of 2009, the Hemopurifier® has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. Aethlon believes the Hemopurifier® is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies.
James A. Joyce, Chairman and CEO of Aethlon, in his 2008 publication, The Broad-Spectrum Treatment of Biological Weapons and Emerging Pandemic Threats, writes:
“The advancement of single-target drug and vaccine therapies as the predominant strategy to address a universe of known and unknown bioterror and pandemic threats is clinically and economically unfeasible. Accordingly, the Department of Health and Human Services (HHS) of the United States has decreed that broad-spectrum therapies, able to demonstrate effectiveness in combating multiple pathogens, will become a focal point for government initiatives that encourage the development of countermeasures against bioterror and pandemic threats.”
Rather than focus efforts on combating a single virus, Aethlon’s more modern approach to combating such pandemics seems to be paying off. To date, the data further reinforces the company’s position of the Hemopurifier® as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Truly remarkable.
Aethlon at Forefront of Broad-Spectrum Virus Treatment With Hemopurifier (From June... RedChip Article)
As the world population continues to grow and distances between people dwindle, a different kind of threat to personal safety, other than bullets, bombs, natural disasters or accidents, is much on the minds of our globally connected population: germs. More specifically, global pandemics of deadly germs.
According to the World Health Organization, nearly 36 thousand people in 76 countries have been infected with the H1N1 virus (Swine flu), causing 163 deaths. As fears that the virus may mutate to a more potent strain mount, the lesson is clear: more people plus more travel equals more germ transmission. While outbreaks of deadly diseases in the past (and present) such as Typhoid fever and influenza are horrific, humankind’s effort and scientific achievements in the name of combating such diseases are truly awe-inspiring.
One such innovator is Aethlon Medical, Inc. (OTC BB: AEMD), developer of the Hemopurifier®. The Hemopurifier is a patented extracorporeal device that captures circulating viruses and viral proteins and toxins before the occurrence of cell and organ infection. The filtration device has already seen significant results in the treatment of HIV, Hepatitus C, Marburg, Ebola, Measles, Mumps, influenza (including the strain of H1N1 that left 57 people dead in the U.S. earlier this year), and Orthopox virus. The Hemopurifier is classified as a broad-spectrum antiretroviral — broad-spectrum inhibitors are naturally occurring antiviral compounds occurring in certain kinds of mushrooms and fungi.
On May 5, 2009, Aethlon reported the following:
“[A]n HIV-infected individual, who received 12 Hemopurifier® treatments during the span of one month, had an average viral load reduction of 55% during each four-hour Hemopurifier® treatment. The study was conducted in the absence of any antiviral drug therapy. Based on this data, mathematical treatment models of approximately 1.5 days of continuous Hemopurifier® treatment would reduce patient viral load to undetectable levels.”
The problem with viral diseases, as anyone who has received a flu shot in the spring knows, is that they are continually evolving. The AIDS and HIV viruses are the most notorious cases of this, and their continually evolving resistance to treatment methods makes them among some of the deadliest in the world. Treatments for such viruses involve multiple-medication “cocktails” taken several times a day, and side effects can include nausea, diarrhea, malaise, and fatigue. Tantamount to finding effective treatments is the goal of finding treatments that improve the patient’s quality of life overall as well as reduce viral load in the bloodstream, as months of treatment can be physically, mentally and emotionally debilitating.
Aethlon’s Hemopurifier is remarkable not only because initial observations from the HIV study indicate the device could inhibit and reverse HIV disease progression in the absence of antiviral drugs but also because the same device may be usable for treating different viral diseases. Since the beginning of 2009, the Hemopurifier® has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. Aethlon believes the Hemopurifier® is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies.
James A. Joyce, Chairman and CEO of Aethlon, in his 2008 publication, The Broad-Spectrum Treatment of Biological Weapons and Emerging Pandemic Threats, writes:
“The advancement of single-target drug and vaccine therapies as the predominant strategy to address a universe of known and unknown bioterror and pandemic threats is clinically and economically unfeasible. Accordingly, the Department of Health and Human Services (HHS) of the United States has decreed that broad-spectrum therapies, able to demonstrate effectiveness in combating multiple pathogens, will become a focal point for government initiatives that encourage the development of countermeasures against bioterror and pandemic threats.”
Rather than focus efforts on combating a single virus, Aethlon’s more modern approach to combating such pandemics seems to be paying off. To date, the data further reinforces the company’s position of the Hemopurifier® as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Truly remarkable.
Aethlon at Forefront of Broad-Spectrum Virus Treatment With Hemopurifier (From June... RedChip Article)
As the world population continues to grow and distances between people dwindle, a different kind of threat to personal safety, other than bullets, bombs, natural disasters or accidents, is much on the minds of our globally connected population: germs. More specifically, global pandemics of deadly germs.
According to the World Health Organization, nearly 36 thousand people in 76 countries have been infected with the H1N1 virus (Swine flu), causing 163 deaths. As fears that the virus may mutate to a more potent strain mount, the lesson is clear: more people plus more travel equals more germ transmission. While outbreaks of deadly diseases in the past (and present) such as Typhoid fever and influenza are horrific, humankind’s effort and scientific achievements in the name of combating such diseases are truly awe-inspiring.
One such innovator is Aethlon Medical, Inc. (OTC BB: AEMD), developer of the Hemopurifier®. The Hemopurifier is a patented extracorporeal device that captures circulating viruses and viral proteins and toxins before the occurrence of cell and organ infection. The filtration device has already seen significant results in the treatment of HIV, Hepatitus C, Marburg, Ebola, Measles, Mumps, influenza (including the strain of H1N1 that left 57 people dead in the U.S. earlier this year), and Orthopox virus. The Hemopurifier is classified as a broad-spectrum antiretroviral — broad-spectrum inhibitors are naturally occurring antiviral compounds occurring in certain kinds of mushrooms and fungi.
On May 5, 2009, Aethlon reported the following:
“[A]n HIV-infected individual, who received 12 Hemopurifier® treatments during the span of one month, had an average viral load reduction of 55% during each four-hour Hemopurifier® treatment. The study was conducted in the absence of any antiviral drug therapy. Based on this data, mathematical treatment models of approximately 1.5 days of continuous Hemopurifier® treatment would reduce patient viral load to undetectable levels.”
The problem with viral diseases, as anyone who has received a flu shot in the spring knows, is that they are continually evolving. The AIDS and HIV viruses are the most notorious cases of this, and their continually evolving resistance to treatment methods makes them among some of the deadliest in the world. Treatments for such viruses involve multiple-medication “cocktails” taken several times a day, and side effects can include nausea, diarrhea, malaise, and fatigue. Tantamount to finding effective treatments is the goal of finding treatments that improve the patient’s quality of life overall as well as reduce viral load in the bloodstream, as months of treatment can be physically, mentally and emotionally debilitating.
Aethlon’s Hemopurifier is remarkable not only because initial observations from the HIV study indicate the device could inhibit and reverse HIV disease progression in the absence of antiviral drugs but also because the same device may be usable for treating different viral diseases. Since the beginning of 2009, the Hemopurifier® has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. Aethlon believes the Hemopurifier® is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies.
James A. Joyce, Chairman and CEO of Aethlon, in his 2008 publication, The Broad-Spectrum Treatment of Biological Weapons and Emerging Pandemic Threats, writes:
“The advancement of single-target drug and vaccine therapies as the predominant strategy to address a universe of known and unknown bioterror and pandemic threats is clinically and economically unfeasible. Accordingly, the Department of Health and Human Services (HHS) of the United States has decreed that broad-spectrum therapies, able to demonstrate effectiveness in combating multiple pathogens, will become a focal point for government initiatives that encourage the development of countermeasures against bioterror and pandemic threats.”
Rather than focus efforts on combating a single virus, Aethlon’s more modern approach to combating such pandemics seems to be paying off. To date, the data further reinforces the company’s position of the Hemopurifier® as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Truly remarkable.
>1M in volume already
Remember when I alerted AEMD here? :) (link back)
Aethlon Medical Discloses Live Webcast of Today's BIOCOM Presentation
Monday 10/26/2009 5:00 AM ET - Pr Newswire
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed that today's presentation at the 4th Annual BIOCOM Investor Conference will be webcast live today. The presentation by Aethlon Chairman and CEO, James A. Joyce will begin at 2 p.m. pacific time and can be accessed on an audio-only basis at:
http://www.biocom.org/event/2009_Investor_Conference
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-
Aethlon Medical Discloses Live Webcast of Today's BIOCOM Presentation
Monday 10/26/2009 5:00 AM ET - Pr Newswire
Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed that today's presentation at the 4th Annual BIOCOM Investor Conference will be webcast live today. The presentation by Aethlon Chairman and CEO, James A. Joyce will begin at 2 p.m. pacific time and can be accessed on an audio-only basis at:
http://www.biocom.org/event/2009_Investor_Conference
(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-